Table 1 Major resistance pathways for currently available INSTIs
From: What if HIV were unable to develop resistance against a new therapeutic agent?
| Raltegravir/Elvitegravir | Dolutegravir |
|---|---|
| Y143 pathway | |
| Y143C | |
| Y143R | |
| T97A/Y143C | |
| T97A/Y143R | |
| L74M/T97A/Y143G | |
| L74M/T97A/E138A/Y143C | R263K |
| N155H pathway | |
| N155H | |
| L74M/N155H | |
| E92Q/N155H | |
| E92Q pathway | |
| E92Q | |
| T66I/E92Q | |
| E92Q/S153A | |
| E92Q/H51Y/L768V | |
| Q148 pathway | |
| Q148H | |
| Q148K | |
| Q148R | |
| E138K/Q148H | |
| E138K/Q148K | |
| E138K/Q148R | |
| G140S/Q148H | |
| G140S/Q148K | |
| G140S/Q148R | |
| E138A/G140S/Y143H/Q148H |